Search results for " OMA"

showing 10 items of 79 documents

Guodunites, a low-palaeolatitude and trans-panthalassic Smithian (Early Triassic) ammonoid genus

2009

11 pages; International audience; Based on new, bed-rock controlled material from Oman and Utah, USA, the Early Triassic genus Guodunites, which was recently erected on the basis of scarce specimens from northwestern Guangxi, South China, is now shown to be a representative of Proptychitidae. This solves the question of the previously unknown phylogenetic affinity of this genus. The genus is restricted to the late middle Smithian, and to date, its biogeographical distribution comprises Oman, South China and Utah, thus indicating an essentially low palaeolatitudinal distribution during the Early Triassic. Its palaeobiogeographical distribution further strengthens the existence of significant…

010506 paleontologySouth chinaOmanCeratitida • oceanic currents • Oman • Proptychitidae • Smithian (Early Triassic) • South China • UtahEarly TriassicCeratitida10125 Paleontological Institute and Museum010502 geochemistry & geophysics01 natural sciencesUtah.Paleontologyoceanic currentsGenusUtahCeratitidaSouth ChinaEcology Evolution Behavior and Systematics0105 earth and related environmental sciencesTerranebiologyPaleontologyProptychitidaebiology.organism_classification1911 Paleontology1105 Ecology Evolution Behavior and Systematics560 Fossils & prehistoric lifeBiological dispersal[SDU.STU.PG]Sciences of the Universe [physics]/Earth Sciences/PaleontologyGeologySmithian (Early Triassic)
researchProduct

New and interesting Orthoptera from the Arabian Peninsula and Socotra.

2017

Abstract This paper reports on some interesting taxa recently found in the Arabian Peninsula and the island of Socotra. Among them is a new species of brachypterous grasshopper Sphodromerus carapezzanus sp. n. (Acrididae: Calliptaminae), described from an isolated area in Dhofar (Oman). A female Heteracris hemiptera (Uvarov, 1935) (Acrididae: Eyprepocnemidinae) is reported, with morphological characters which do not fully comply with those of any known subspecies. Two species, hitherto rarely documented, are also reported, Phaneroptila insularis Uvarov, 1957 (Tettigoniidae: Phaneropterinae) from Socotra and Cataloipus thomasi Uvarov, 1933 (Acrididae: Eyprepocnemidinae) from Oman. Pycnodicty…

0106 biological sciencesSphodromerus carapezzanus sp. n.food.ingredientInsectaArthropodaOmanShort CommunicationTettigoniidae010607 zoologySubspecies010603 evolutionary biology01 natural sciencesAcrididaetaxonomyfoodCataloipuslcsh:ZoologyTettigoniidaeAnimalialcsh:QL1-991Grasshoppernew records new species Oman Sphodromerus carapezzanus sp. n. taxonomyEcology Evolution Behavior and Systematicsnew speciesbiologyEcologynew recordsbiology.organism_classificationAcrididaeSettore AGR/11 - Entomologia Generale E ApplicataTaxonGeographyOrthopteraAnimal Science and ZoologyTaxonomy (biology)PhaneropterinaeZooKeys
researchProduct

Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.

2020

Background: Current availability of several biologic treatments for severe asthma makes it possible to choose the most appropriate for each patient. Sometimes a good percentage of patients with severe asthma may be eligible for biologics that target either the allergic phenotype or the eosinophilic one, but not all respond to that selected as first choice. The aim of our real-life study was to assess whether, for patients with severe eosinophilic allergic asthma, not previously controlled by the anti-IgE omalizumab, the shift to another biologic targeting interleukin-5, such as mepolizumab, may represent a good therapeutic choice. Methods: A total of 41 consecutive patients with severe, per…

AdultMale0301 basic medicinePulmonary and Respiratory Medicinesevere asthmamedicine.medical_specialtyTime FactorsSevere asthmamepolizumab omalizumab severe asthma switchingOmalizumabSettore MED/10 - Malattie Dell'Apparato RespiratorioAntibodies Monoclonal HumanizedSeverity of Illness Index03 medical and health sciences0302 clinical medicinereal lifeAnti-Allergic AgentsHumansMedicineswitching.Pharmacology (medical)Anti-Asthmatic AgentsPulmonary EosinophiliaIntensive care medicineLungOriginal ResearchAgedRetrospective Studieslcsh:RC705-779switchingDrug Substitutionbusiness.industrymepolizumablcsh:Diseases of the respiratory systemMiddle AgedAsthmaTreatment Outcome030104 developmental biologyItaly030228 respiratory systemomalizumabFemalebusinessMepolizumabmedicine.drug
researchProduct

Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy

2015

Few data are available on the proportion of asthmatics achieving a good asthma control (according GINA guidelines) and on the level of airway inflammation during omalizumab treatment. The aim of this cross-sectional national observational study was to assess the level of control (according to GINA guidelines) achieved in a group of asthmatics on omalizumab treatment, and to characterize the factors that influence the lack of control. We studied 306 asthmatics under omalizumab treatment for a median of 32 months (range 4-120). The level of control according to GINA was good in 25.2%, partial in 47.1% and poor in 24.5% of patients (data were missing for the remaining 3.2%). Comparison between…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyExacerbationCross-sectional studyOmalizumabOmalizumabComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioExhaled nitric oxide; Exacerbations; Comorbidities; Asthma; Omalizumab; ControlSeverity of Illness IndexComorbiditiesExacerbationsExhaled nitric oxideInternal medicineSeverity of illnessControlMedicineAnti-Asthmatic AgentHumansPharmacology (medical)Anti-Asthmatic AgentsInflammation MediatorAsthmaRespiratory Function TestAgedCross-Sectional Studiebusiness.industryBiochemistry (medical)ExacerbationMiddle Agedmedicine.diseaseComorbidityAsthmaRespiratory Function TestsCross-Sectional StudiesItalyExhaled nitric oxidePhysical therapyObservational studyAsthma; Comorbidities; Control; Exacerbations; Exhaled nitric oxide; Omalizumab; Adult; Aged; Anti-Asthmatic Agents; Asthma; Comorbidity; Cross-Sectional Studies; Female; Humans; Inflammation Mediators; Italy; Male; Middle Aged; Omalizumab; Respiratory Function Tests; Severity of Illness Index; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)FemaleComorbiditieInflammation Mediatorsbusinessmedicine.drugHuman
researchProduct

Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes

2019

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaTreatment outcomeMEDLINEOmalizumabOmalizumabSettore MED/10 - Malattie Dell'Apparato RespiratorioImmunoglobulin Eeosinophil Omalizumab anti-IgE asthmaLeukocyte CountText miningForced Expiratory VolumeInternal medicineEosinophiliamedicineHumansImmunology and AllergyAnti-Asthmatic AgentsBlood eosinophilAgedRetrospective StudiesAsthmabiologybusiness.industryRetrospective cohort studyMiddle AgedasthmaPrognosismedicine.diseaseEosinophilsTreatment Outcomeinflammationbiology.proteinFemalebusinessmedicine.drug
researchProduct

Effects of Omalizumab Treatment in Patients With Recalcitrant Nasal Polyposis and Mild Asthma: A Multicenter Retrospective Study

2021

Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a clinical entity with specific features that impacts significantly on patient quality of life (QoL). CRSwNP is often associated with asthma and is difficult to control and manage despite pharmacological and/or surgical treatment. Omalizumab, a monoclonal anti-IgE antibody, has emerged as a putative therapeutic option. Objective To evaluate the effects of omalizumab on nasal polyp (NP) size and QoL assessed by Sino-Nasal Outcome Test-22 (SNOT-22) in patients with recalcitrant CRSwNP and mild asthma. Methods A multicenter retrospective analysis of patient data from the Community of Valencia (Spain) was performed. Adult patients …

Adultmedicine.medical_specialtyMild asthmaOmalizumabOmalizumabaspirin-exacerbated respiratory diseasechronic rhinosinusitis with nasal polypsImmunoglobulin E03 medical and health sciencesNasal Polyps0302 clinical medicineQuality of lifeSNOT-22Internal medicinemedicineHumansImmunology and AllergyNasal polypsIn patient030223 otorhinolaryngologyRetrospective StudiesRhinitisnasal polypsbiologybusiness.industrytotal nasal endoscopic polyp scoreRetrospective cohort studyGeneral Medicinemedicine.diseaseAsthmaTreatment Outcomequality of lifetissue eosinophilia030228 respiratory systemOtorhinolaryngologyIgE SNOT-22 aspirin-exacerbated respiratory disease chronic rhinosinusitis with nasal polyps mild asthma nasal polyps omalizumab quality of life tissue eosinophilia total nasal endoscopic polyp scoreChronic DiseaseQuality of Lifebiology.proteinomalizumabAspirin exacerbated respiratory diseaseIgEbusinessmild asthmamedicine.drugAmerican Journal of Rhinology & Allergy
researchProduct

Can the response to Omalizumab be influenced by treatment duration? A real-life study

2017

Objective It is unknown whether Omalizumab effectiveness changes over the course of time. Our retrospective real-life study tried to analyze whether Omalizumab response may be influenced by treatment duration. Methods 340 severe asthmatics treated with Omalizumab for different periods of time were recruited. They were subdivided into 4 groups according to the Omalizumab treatment length: 60 months. Omalizumab treatment results (FEV1, exacerbations, ACT, SABA use, asthma control levels, medications used e and ICS doses) were compared. Results ACT, exacerbations, GINA control levels, ICS doses and SABA use were similar in all groups with different Omalizumab treatment durations. Using a linea…

CyclopropanesMaleSevere asthmaTime FactorsTreatment durationQuinolineEffectivenessOmalizumabOmalizumabAcetatesAdrenal Cortex Hormone0302 clinical medicineAdrenal Cortex HormonesRetrospective StudieForced Expiratory VolumeMedicinePharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicineLead (electronics)Adrenergic beta-AgonistConfoundingEffectiveneReal-lifeResponseAdrenergic beta-AgonistsMiddle AgedTreatment OutcomeEffectiveness; Omalizumab; Real-life; Response; Severe asthma; Treatment duration; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)QuinolinesLinear ModelFemaleHumanmedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyTime FactorSulfidesSettore MED/10 - Malattie Dell'Apparato RespiratorioTreatment duration03 medical and health sciencesInternal medicineHumansAnti-Asthmatic AgentMontelukastRetrospective StudiesAsthmaAcetatebusiness.industryBiochemistry (medical)Retrospective cohort studymedicine.diseaseAsthmaDiscontinuationSurgery030228 respiratory systemLinear ModelsbusinessPulmonary Pharmacology & Therapeutics
researchProduct

Children at risk for dyslexia show deficient left-hemispheric memory representations for new spoken word forms

2021

Developmental dyslexia is a specific learning disorder with impairments in reading and spelling acquisition. Apart from literacy problems, dyslexics show inefficient speech encoding and deficient novel word learning, with underlying problems in phonological processing and learning. These problems have been suggested to be related to deficient specialization of the left hemisphere for language processing. To examine this possibility, we tracked with magnetoencephalography (MEG) the activation of the bilateral temporal cortices during formation of neural memory traces for new spoken word forms in 7–8-year-old children with high familial dyslexia risk and in controls. The at-risk children impr…

DyslexiaMEGkielellinen kehitysPhonological learningkielen omaksuminenReading acquisitiondysleksiaMagnetoencephalographylcsh:Neurosciences. Biological psychiatry. Neuropsychiatrymuisti (kognitio)fonologinen tietoisuuslcsh:RC321-571
researchProduct

Socialization, language choice and belonging : language norms in a first and second grade English medium class

2012

English medium educationetnografialanguage socializationluokkatyöskentelykielikylpyethnographysosiolingvistiikkasosialisaatiovieraskielinen opetuskielen omaksuminenopetusmenetelmätclassroom interactionkielellinen vuorovaikutusenglannin kieli
researchProduct

Femminismo islamico e cosmopolitismo

2021

The chapter introduces Islamic feminism as a movement with a focus on three study cases from Egypt (Omaima Abou-Bakr), Iran (Ziba Mir-Hosseini), and the United States (Amina Wadud). In my section, I claim that besides being a social commitment, Islamic feminism is a form of moral cosmopolitanism, for it is a global and transnational movement. The advocacy of Islamic feminists is rooted in local contexts, at the same time they are involved in empowering international networks which allow them to meet activists from other domains, enforce their projects, share their experiences and work together for achieving their goals. The name “cosmopolitan Islamic feminist” is not an oxymoron, since it d…

Islamic feminism Cosmopolitanism Omaima Abou-Bakr Amina Wadud Ziba Mir-Hosseini Islamic Ethics Human rights.
researchProduct